Crinetics Pharmaceuticals Announces Long-Term Data for Palsonify
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Crinetics Pharmaceuticals announced new long-term data from its clinical development program evaluating novel Palsonify in acromegaly during an oral presentation at the Endocrine Society's Annual Meeting, ENDO 2026. Notably, pooled data from the open-label extension, OLE, trials of Pathfndr-1 and Pathfndr-2 show that after two years of treatment, Palsonify was effective and well-tolerated in patients who were switched from standard-of-care monthly injectable somatostatin receptor ligands and those who were medically untreated, respectively, when oral, once-daily Palsonify was initiated.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.750
Low
67.00
Averages
89.40
High
105.00
Current: 35.750
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crinetics Presents Phase 2 Data for Atumelnant at ENDO 2026
- Clinical Trial Progress: Crinetics presented Phase 2 data for Atumelnant in congenital adrenal hyperplasia (CAH) at ENDO 2026, showing a significant 67% average reduction in A4 morning serum levels among 38 participants, indicating strong efficacy of the drug.
- Safety Assessment: In the CAH trial, 88% of participants achieved a physiological daily dose of glucocorticoids, and Atumelnant was generally well tolerated with no treatment-related severe adverse events, highlighting its potential for clinical use.
- Cushing's Syndrome Study: In the Phase 1b/2a study for ACTH-dependent Cushing's syndrome, Atumelnant rapidly lowered early morning serum cortisol levels over a 10-day treatment period, with 3 out of 6 participants maintaining 24-hour urine free cortisol levels below the upper limit of normal, demonstrating promising efficacy.
- Future Development Direction: Based on these positive clinical trial results, Crinetics plans to advance Atumelnant into late-phase clinical development, further validating its application potential in treating rare endocrine diseases.
See More
Crinetics' Atumelnant Significantly Reduces Androgens in CAH Treatment
- Significant Androgen Reduction: Crinetics' atumelnant demonstrated an average 67% reduction in morning serum androstenedione levels over 12 weeks in adults with classic CAH, highlighting its potential as a new treatment option for patients needing effective androgen control.
- Glucocorticoid Dose Reduction: In the Phase 2 trial, 88% of participants maintained physiological glucocorticoid levels despite dose reductions, indicating atumelnant's efficacy in managing hormone levels without compromising treatment outcomes, enhancing its clinical applicability.
- Rapid Cortisol Lowering: In the Phase 1b/2a trial for ACTH-dependent Cushing's syndrome, atumelnant rapidly lowered early morning serum cortisol levels within 10 days, with 3 out of 6 participants maintaining urinary free cortisol within normal limits, showcasing its therapeutic effectiveness.
- Good Tolerability: Atumelnant exhibited good tolerability across all participants, with no severe adverse events reported, indicating its safety profile and paving the way for broader clinical use in endocrine disorders.
See More
PALSONIFY Shows Long-Term Efficacy in Acromegaly at ENDO 2026
- Long-Term Efficacy: Data from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies show that after two years of treatment, PALSONIFY effectively maintains IGF-1 levels and stable symptoms, highlighting its potential in treating acromegaly patients.
- Tumor Volume Stability: In the PATHFNDR-1 study, 93% of 53 participants entered the ongoing trial, with pituitary tumor volumes remaining stable at 48 weeks, indicating PALSONIFY's effectiveness in tumor control.
- Combination Therapy Benefits: In the ACROBAT study, the combination of PALSONIFY with oral cabergoline further improved IGF-1 levels in patients whose levels had not yet normalized, demonstrating the potential advantages of combination therapy and its good tolerability.
- Safety Profile: Among 167 participants, the most common adverse events were diarrhea (15.6%) and arthralgia (11.4%), with no new safety signals identified, indicating that long-term use of PALSONIFY is safe.
See More
Crinetics Releases Long-Term Data on PALSONIFY for Acromegaly
- Clinical Trial Results: Data from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies show that after two years of treatment, PALSONIFY effectively maintained IGF-1 levels and stable symptoms, highlighting its potential in treating acromegaly patients.
- Tumor Volume Changes: In the PATHFNDR-2 study, 114 patients had a baseline IGF-1 level of 1.64×ULN, which decreased to 1.06×ULN after 48 weeks of treatment, with 7 patients experiencing over a 20% reduction in pituitary tumor volume, demonstrating PALSONIFY's efficacy.
- Safety Assessment: Among 167 participants, the most common adverse events included diarrhea (15.6%) and arthralgia (11.4%), with no new safety signals identified, indicating that long-term use of PALSONIFY is safe.
- Combination Therapy Benefits: In the ACROBAT study, the combination of PALSONIFY with oral cabergoline further improved IGF-1 levels, suggesting that combination therapy may offer enhanced management options for acromegaly patients, potentially providing better treatment outcomes.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Presentation: Crinetics will showcase six abstracts at the 2026 Endocrine Society Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which is expected to boost market confidence and drive sales growth.
- New Drug Research Progress: Full Phase 2 study results for atumelnant will be presented, demonstrating its effectiveness in congenital adrenal hyperplasia, potentially introducing new treatment options in this field and enhancing Crinetics' competitive edge in endocrine disease management.
- Diverse Presentation Formats: Crinetics will conduct oral reports and poster presentations covering the long-term safety and efficacy of PALSONIFY in combination with cabergoline, as well as its real-world application in managing acromegaly, further solidifying its market position.
- Patient Engagement Activity: Crinetics will host a product theater on June 15, inviting patients to share their experiences with PALSONIFY, aiming to enhance interaction with healthcare professionals through patient stories, thereby increasing brand awareness and patient loyalty.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Showcase: Crinetics will present six abstracts at the 2026 ENDO Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which could enhance market recognition and drive sales growth.
- Rich Research Findings: The studies on PALSONIFY include results from open-label extension studies lasting up to two years, demonstrating its effectiveness in controlling IGF-1 levels, potentially providing patients with optimized treatment options and enhancing the company's competitiveness in the endocrine disease sector.
- Atumelnant Progress: Crinetics will also showcase full Phase 2 study data for atumelnant in congenital adrenal hyperplasia, indicating its potential to lower glucocorticoid doses, which may offer new solutions for treating ACTH-dependent Cushing's syndrome.
- Product Promotion Event: Crinetics will host a product theater on June 15 titled “Advancing Acromegaly Management,” which aims to enhance PALSONIFY's market awareness by bridging clinical evidence with the patient journey, thereby improving patient treatment experiences.
See More
Crinetics Presents Phase 2 Data for Atumelnant at ENDO 2026
- Clinical Trial Progress: Crinetics presented Phase 2 data for Atumelnant in congenital adrenal hyperplasia (CAH) at ENDO 2026, showing a significant 67% average reduction in A4 morning serum levels among 38 participants, indicating strong efficacy of the drug.
- Safety Assessment: In the CAH trial, 88% of participants achieved a physiological daily dose of glucocorticoids, and Atumelnant was generally well tolerated with no treatment-related severe adverse events, highlighting its potential for clinical use.
- Cushing's Syndrome Study: In the Phase 1b/2a study for ACTH-dependent Cushing's syndrome, Atumelnant rapidly lowered early morning serum cortisol levels over a 10-day treatment period, with 3 out of 6 participants maintaining 24-hour urine free cortisol levels below the upper limit of normal, demonstrating promising efficacy.
- Future Development Direction: Based on these positive clinical trial results, Crinetics plans to advance Atumelnant into late-phase clinical development, further validating its application potential in treating rare endocrine diseases.
See More
Crinetics' Atumelnant Significantly Reduces Androgens in CAH Treatment
- Significant Androgen Reduction: Crinetics' atumelnant demonstrated an average 67% reduction in morning serum androstenedione levels over 12 weeks in adults with classic CAH, highlighting its potential as a new treatment option for patients needing effective androgen control.
- Glucocorticoid Dose Reduction: In the Phase 2 trial, 88% of participants maintained physiological glucocorticoid levels despite dose reductions, indicating atumelnant's efficacy in managing hormone levels without compromising treatment outcomes, enhancing its clinical applicability.
- Rapid Cortisol Lowering: In the Phase 1b/2a trial for ACTH-dependent Cushing's syndrome, atumelnant rapidly lowered early morning serum cortisol levels within 10 days, with 3 out of 6 participants maintaining urinary free cortisol within normal limits, showcasing its therapeutic effectiveness.
- Good Tolerability: Atumelnant exhibited good tolerability across all participants, with no severe adverse events reported, indicating its safety profile and paving the way for broader clinical use in endocrine disorders.
See More
PALSONIFY Shows Long-Term Efficacy in Acromegaly at ENDO 2026
- Long-Term Efficacy: Data from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies show that after two years of treatment, PALSONIFY effectively maintains IGF-1 levels and stable symptoms, highlighting its potential in treating acromegaly patients.
- Tumor Volume Stability: In the PATHFNDR-1 study, 93% of 53 participants entered the ongoing trial, with pituitary tumor volumes remaining stable at 48 weeks, indicating PALSONIFY's effectiveness in tumor control.
- Combination Therapy Benefits: In the ACROBAT study, the combination of PALSONIFY with oral cabergoline further improved IGF-1 levels in patients whose levels had not yet normalized, demonstrating the potential advantages of combination therapy and its good tolerability.
- Safety Profile: Among 167 participants, the most common adverse events were diarrhea (15.6%) and arthralgia (11.4%), with no new safety signals identified, indicating that long-term use of PALSONIFY is safe.
See More
Crinetics Releases Long-Term Data on PALSONIFY for Acromegaly
- Clinical Trial Results: Data from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies show that after two years of treatment, PALSONIFY effectively maintained IGF-1 levels and stable symptoms, highlighting its potential in treating acromegaly patients.
- Tumor Volume Changes: In the PATHFNDR-2 study, 114 patients had a baseline IGF-1 level of 1.64×ULN, which decreased to 1.06×ULN after 48 weeks of treatment, with 7 patients experiencing over a 20% reduction in pituitary tumor volume, demonstrating PALSONIFY's efficacy.
- Safety Assessment: Among 167 participants, the most common adverse events included diarrhea (15.6%) and arthralgia (11.4%), with no new safety signals identified, indicating that long-term use of PALSONIFY is safe.
- Combination Therapy Benefits: In the ACROBAT study, the combination of PALSONIFY with oral cabergoline further improved IGF-1 levels, suggesting that combination therapy may offer enhanced management options for acromegaly patients, potentially providing better treatment outcomes.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Presentation: Crinetics will showcase six abstracts at the 2026 Endocrine Society Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which is expected to boost market confidence and drive sales growth.
- New Drug Research Progress: Full Phase 2 study results for atumelnant will be presented, demonstrating its effectiveness in congenital adrenal hyperplasia, potentially introducing new treatment options in this field and enhancing Crinetics' competitive edge in endocrine disease management.
- Diverse Presentation Formats: Crinetics will conduct oral reports and poster presentations covering the long-term safety and efficacy of PALSONIFY in combination with cabergoline, as well as its real-world application in managing acromegaly, further solidifying its market position.
- Patient Engagement Activity: Crinetics will host a product theater on June 15, inviting patients to share their experiences with PALSONIFY, aiming to enhance interaction with healthcare professionals through patient stories, thereby increasing brand awareness and patient loyalty.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Showcase: Crinetics will present six abstracts at the 2026 ENDO Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which could enhance market recognition and drive sales growth.
- Rich Research Findings: The studies on PALSONIFY include results from open-label extension studies lasting up to two years, demonstrating its effectiveness in controlling IGF-1 levels, potentially providing patients with optimized treatment options and enhancing the company's competitiveness in the endocrine disease sector.
- Atumelnant Progress: Crinetics will also showcase full Phase 2 study data for atumelnant in congenital adrenal hyperplasia, indicating its potential to lower glucocorticoid doses, which may offer new solutions for treating ACTH-dependent Cushing's syndrome.
- Product Promotion Event: Crinetics will host a product theater on June 15 titled “Advancing Acromegaly Management,” which aims to enhance PALSONIFY's market awareness by bridging clinical evidence with the patient journey, thereby improving patient treatment experiences.
See More
